| Non-Hodgkin Lymphoma (NHL) |
1 |
1 |
| Biologic Therapy |
0 |
1 |
| CAR-T |
0 |
0.8 |
| B-Cell Lymphoma |
0 |
0.8 |
| Hodgkin Lymphoma |
0 |
0.8 |
| Lymphoma |
0 |
0.54 |
| Monoclonal Antibody |
0 |
0.31 |
| Refractory |
0 |
0.31 |
| Antineoplastic Drug |
0 |
0.29 |
| Immunomodulator |
0 |
0.23 |
| Toxicology |
0 |
0.2 |
| Antibody Drug Conjugates |
0 |
0.15 |
| Multiple Myeloma |
0 |
0.14 |
| Stem Cell Research and Therapy |
0 |
0.14 |
| Autologous stem cell transplant |
0 |
0.11 |
| Adverse Effects |
0 |
0.08 |
| Antigens |
0 |
0.08 |
| Blood |
0 |
0.08 |
| Cancer |
0 |
0.08 |
| Chemotherapy |
0 |
0.08 |
| Clinical Research |
0 |
0.08 |
| Complementary and Alternative Medicine |
0 |
0.08 |
| Cytokines |
0 |
0.08 |
| Food and Drug Administration (FDA) |
0 |
0.08 |
| Healthcare and Medical Technology |
0 |
0.08 |
| Immunotherapy |
0 |
0.08 |
| Intravenous |
0 |
0.08 |
| Lymphocytes |
0 |
0.08 |
| Patient Safety |
0 |
0.08 |
| Receptors |
0 |
0.08 |
| Transplantation |
0 |
0.08 |